ArticleInfluenza and other respiratory viruses2024
Comparative analysis of mortality in patients admitted with an infection with influenza A/B virus, respiratory syncytial virus, rhinovirus, metapneumovirus or SARS-CoV-2.
Article in Influenza and other respiratory viruses, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The Global Burden of Human Metapneumovirus in High-Risk Adults: A Systematic Literature Review and Meta-Analysis.Journal of epidemiology and global health · 2026Pooled it
- Comparing outcomes of COVID-19 and influenza among hospitalized adults in the European severe acute respiratory infection vaccine effectiveness (EuroSAVE) network, 2021-2024: a retrospective cohort analysis.The Lancet regional health. Europe · 2026Article
- Comparison of Healthcare Resource Utilization and Disease Outcomes in Adults Hospitalized with Human Metapneumovirus and Respiratory Syncytial Virus.The Journal of infectious diseases · 2026Article
- Article
- Characteristics and Outcomes of Patients With Hematologic Malignancies Hospitalized With Respiratory Viral Infections.Open forum infectious diseases · 2026Article
- Severe outcomes of individual or multiple respiratory viral infections in a large national healthcare system, 2022-2023.Frontiers in public health · 2026Article
- Disease burden of influenza in Spain: A five-season study (2015-2020).Human vaccines & immunotherapeutics · 2025Article
- Spray-Dried Serum for Inhaled Antiviral Therapy.Pharmaceutics · 2025Article
- Impact of respiratory viruses detection on outcomes in ventilated nosocomial pneumonia: an exposed/unexposed study.Annals of intensive care · 2025Article
- Human metapneumovirus: understanding the molecular mechanisms and pathology of infection.Journal of virology · 2025Review
- Surveillance of respiratory viruses in severe acute respiratory infections in Southern Brazil, 2023-2024.BMC infectious diseases · 2025Article
- Comparative Performance of Digital PCR and Real-Time RT-PCR in Respiratory Virus Diagnostics.Viruses · 2025Article
- Rhinovirus, an Age-Old Problem Yet to be Solved: A Comprehensive Review Discussing Modern Therapeutics.Health science reports · 2025Article
- Review
- Clinical Features and Gene Expression Patterns in Adults Hospitalized With Respiratory Syncytial Virus and Human Metapneumovirus Infection.The Journal of infectious diseases · 2025Article
- Characteristics of Human Metapneumovirus Infection Compared to Respiratory Syncytial Virus and Influenza Infections in Adults Hospitalized for Influenza-Like Illness in France, 2012-2022.The Journal of infectious diseases · 2025Article
- Computable phenotypes to identify respiratory viral infections in the All of Us research program.Scientific reports · 2025Article
- Role of Respiratory Viruses in Severe Acute Respiratory Failure.Journal of clinical medicine · 2025Review
- Unveiling the Spectrum of Respiratory Syncytial Virus Disease in Adults: From Community to Hospital.Influenza and other respiratory viruses · 2025Article
- Hidden in plain sight: the impact of human rhinovirus infection in adults.Respiratory research · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: While influenza virus and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are recognised as a cause of severe illness and mortality, clinical interest for respiratory syncytial virus (RSV), rhinovirus and human metapneumovirus (hMPV) infections is still limited. Methods: We conducted a retrospective database study comparing baseline characteristics and 30-day mortality in a large cohort of adult patients admitted for an overnight stay or longer with an influenza virus (A/B), rhinovirus, hMPV, RSV or SARS-CoV-2 infection. For non-SARS-CoV-2 viruses, data were included for the period July 2017-February 2020. For SARS-CoV-2, data between March 2020 and March 2022 were included. Results: Covariate-adjusted 30-day mortality following RSV, hMPV or rhinovirus infections was substantial (crude mortality 8-10%) and comparable with mortality following hospitalisation with an influenza A virus infection. Mortality following a SARS-CoV-2 infection was consistently higher than for any other respiratory virus, at any point in time (crude mortality 14-25%). Odds of mortality for SARS-CoV-2 compared with influenza A declined from 4.9 to 1.7 over the course of the pandemic. Patients with SARS-CoV-2 infection had less comorbidity than patients with other respiratory virus infections and were more often male. In this cohort, age was related to mortality following hospitalisation, while an association with comorbidity was not apparent. Conclusions: With the exception of SARS-CoV-2 infections, we find the clinical outcome of common respiratory virus infections requiring hospitalisation more similar than often assumed. The observed mortality from SARS-CoV-2 was significantly higher, but the difference with other respiratory viruses became less distinct over time.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.